Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET/MRI for Monitoring Early Response in Stage IV HER2+ Breast Cancer
NCT04273555Phase 2Withdrawn
- Sponsor
- University of Alabama at Birmingham
- Start
- Mar 2026
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in HER2-positive breast cancer, sponsored by University of Alabama at Birmingham. Primary endpoints: Standardized Uptake Value, Apparent Diffusion Coefficient and 4 more. Planned start Mar 2026; status: withdrawn.
02
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT04273555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04273555.